tirzepatide shortage fda update Breaking News: OFA Challenges on Ruling FDA says that the GLP-1
Description
It copies the effects of two natural hormones that control appetite and digestion GLP-1 and GIP
Semaglutide targets the GLP-1 receptor, whereas Tirzepatide targets both GIP and GLP-1 receptors
The study was funded by the Italian Diabetes Society and partly supported by a grant from Eli Lilly
Average Blood Pressure Reductions Seen in Studies These improvements may seem small, but they can have important cardiovascular implications
Your provider may recommend: Shorter time at the 2.5 mg initiation dose (3 weeks instead of 4) More aggressive titration to reach therapeutic levels sooner Targeting higher maintenance doses (12.5 to 15 mg) from the outset Closer monitoring of side effects to balance speed with tolerance The microdosing alternative for sensitive switchers Not everyone needs or wants to follow the standard titration
doi: 10.1186/s12933-022-01604-7 FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes
